UNASSIGNED: All eligible case-control studies that met the search terms were retrieved in PubMed, Embase, Wanfang Med Online and Chinese National Knowledge Infrastructure (CNKI) databases. We identified seven independent case-control studies with a total of 10,355 subjects from Chinese population up to May 2023. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the susceptibility of ischemic stroke.
UNASSIGNED: Meta-analysis results indicated that rs1122608 polymorphism of LDL-R gene significantly decreased ischemic stroke risk under dominant model (OR = 0.69, 95% CI = 0.54-0.87), heterozygote comparison (OR = 0.69, 95% CI = 0.53-0.92) and allele comparison (OR = 0.74, 95% CI = 0.65-0.84) in overall analysis. Furthermore, pooled analysis showed that significant associations were observed between rs688 polymorphism and ischemic stroke risk in heterozygote carriers (OR = 1.71, 95% CI = 1.07-2.71) and dominant model (OR = 1.67, 95% CI = 1.04-2.68) in Chinese population.
UNASSIGNED: Our comprehensive meta-analysis on the role of LDL-R gene rs1122608 and rs688 polymorphisms in the risk of ischemic stroke revealed that the rs1122608 polymorphism was associated with a decreased risk, while the rs688 polymorphism was associated with an increased risk of ischemic stroke in Chinese population. Further multicenter studies were needed to confirm the effect on the susceptibility of ischemic stroke.
■所有符合搜索条件的合格病例对照研究均在PubMed中检索,Embase,万方医药在线与中国国家知识基础设施(CNKI)数据库截至2023年5月,我们从中国人群中确定了7项独立的病例对照研究,共有10,355名受试者。使用汇总比值比(OR)和95%置信区间(CIs)评估缺血性卒中的易感性。
■Meta分析结果表明,在显性模型下,LDL-R基因rs1122608多态性显著降低缺血性卒中风险(OR=0.69,95%CI=0.54-0.87)。在总体分析中,杂合子比较(OR=0.69,95%CI=0.53-0.92)和等位基因比较(OR=0.74,95%CI=0.65-0.84)。此外,汇总分析表明,在中国人群中,rs688多态性与杂合子携带者(OR=1.71,95%CI=1.07-2.71)和显性模型(OR=1.67,95%CI=1.04-2.68)的缺血性卒中风险之间存在显着关联。
■我们对LDL-R基因rs1122608和rs688多态性在缺血性卒中风险中的作用的综合荟萃分析显示,rs1122608多态性与风险降低相关,而rs688多态性与中国人群缺血性卒中风险增加相关。需要进一步的多中心研究来证实对缺血性卒中易感性的影响。